A dynamic landscape for antibody binding modulates antibody-mediated neutralization of West Nile virus

PLoS Pathogens

Volumn 7, Issue 6, 2011, Pages

  Dowd, Kimberly A ^a   Jost, Christiane A ^a   Durbin, Anna P ^b   Whitehead, Stephen S ^a   Pierson, Theodore C ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT; EPITOPE; MONOCLONAL ANTIBODY; VIRUS ENVELOPE PROTEIN; WEST NILE VACCINE; GLYCOPROTEIN E, FLAVIVIRUS; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY;

ANTIBODY DEPENDENT ENHANCEMENT; ANTIGEN BINDING; ARTICLE; CELL AGGREGATION; DENGUE VIRUS; HALF LIFE TIME; HUMAN; HUMAN CELL; MICROBIAL KINETICS; NONHUMAN; TEMPERATURE; TIME; VIRION; VIRUS MORPHOLOGY; VIRUS NEUTRALIZATION; WEST NILE FLAVIVIRUS; ANTIBODY AFFINITY; CELL LINE; IMMUNOLOGY; METABOLISM; POLYMERASE CHAIN REACTION; VIRUS ATTACHMENT;

DENGUE VIRUS; FLAVIVIRUS; RUMEX; WEST NILE VIRUS;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIBODY AFFINITY; CELL LINE; DENGUE VIRUS; EPITOPES; HUMANS; POLYMERASE CHAIN REACTION; VIRAL ENVELOPE PROTEINS; VIRUS ATTACHMENT; WEST NILE VIRUS;

EID: 79959812241     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1002111     Document Type: Article

References (69)

1. Lindenbach BD, Thiel HJ, Rice CM, (2007) Flaviviridae: The Viruses and Their Replication. In: Knipe DM, Howley PM, editors. Fields Virology. 5th ed Philadelphia Lippincott-Williams & Wilkins pp. 1101-1152.
2. Sejvar JJ, (2007) The long-term outcomes of human West Nile virus infection. Clin Infect Dis 44: 1617-1624.
3. Planitzer CB, Modrof J, Yu MY, Kreil TR, (2009) West Nile virus infection in plasma of blood and plasma donors, United States. Emerg Infect Dis 15: 1668-1670.
4. Fernandez-Garcia MD, Mazzon M, Jacobs M, Amara A, (2009) Pathogenesis of flavivirus infections: using and abusing the host cell. Cell Host Microbe 5: 318-328.
5. Brinton MA, (2002) The molecular biology of West Nile Virus: a new invader of the western hemisphere. Annu Rev Microbiol 56: 371-402.
6. Perera R, Kuhn RJ, (2008) Structural proteomics of dengue virus. Curr Opin Microbiol 11: 369-377.
7. Mackenzie JM, Khromykh AA, Parton RG, (2007) Cholesterol manipulation by West Nile virus perturbs the cellular immune response. Cell Host Microbe 2: 229-239.
8. Roosendaal J, Westaway EG, Khromykh A, Mackenzie JM, (2006) Regulated cleavages at the West Nile virus NS4A-2K-NS4B junctions play a major role in rearranging cytoplasmic membranes and Golgi trafficking of the NS4A protein. J Virol 80: 4623-4632.
9. Laurent-Rolle M, Boer EF, Lubick KJ, Wolfinbarger JB, Carmody AB, et al. (2010) The NS5 protein of the virulent West Nile virus NY99 strain is a potent antagonist of type I interferon-mediated JAK-STAT signaling. J Virol 84: 3503-3515.
10. Munoz-Jordan JL, Sanchez-Burgos GG, Laurent-Rolle M, Garcia-Sastre A, (2003) Inhibition of interferon signaling by dengue virus. Proc Natl Acad Sci U S A 100: 14333-14338.
11. Avirutnan P, Fuchs A, Hauhart RE, Somnuke P, Youn S, et al. (2010) Antagonism of the complement component C4 by flavivirus nonstructural protein NS1. J Exp Med 207: 793-806.
12. Zhang Y, Kaufmann B, Chipman PR, Kuhn RJ, Rossmann MG, (2007) Structure of immature West Nile virus. J Virol 81: 6141-6145.
13. Zhang Y, Corver J, Chipman PR, Zhang W, Pletnev SV, et al. (2003) Structures of immature flavivirus particles. EMBO J 22: 2604-2613.
14. Yu IM, Zhang W, Holdaway HA, Li L, Kostyuchenko VA, et al. (2008) Structure of the immature dengue virus at low pH primes proteolytic maturation. Science 319: 1834-1837.
15. Li L, Lok SM, Yu IM, Zhang Y, Kuhn RJ, et al. (2008) The flavivirus precursor membrane-envelope protein complex: structure and maturation. Science 319: 1830-1834.
16. Allison SL, Schalich J, Stiasny K, Mandl CW, Kunz C, et al. (1995) Oligomeric rearrangement of tick-borne encephalitis virus envelope proteins induced by an acidic pH. J Virol 69: 695-700.
17. Elshuber S, Allison SL, Heinz FX, Mandl CW, (2003) Cleavage of protein prM is necessary for infection of BHK-21 cells by tick-borne encephalitis virus. J Gen Virol 84: 183-191.
18. Guirakhoo F, Bolin RA, Roehrig JT, (1992) The Murray Valley encephalitis virus prM protein confers acid resistance to virus particles and alters the expression of epitopes within the R2 domain of E glycoprotein. Virology 191: 921-931.
19. Davis CW, Nguyen HY, Hanna SL, Sanchez MD, Doms RW, et al. (2006) West Nile virus discriminates between DC-SIGN and DC-SIGNR for cellular attachment and infection. J Virol 80: 1290-1301.
20. Rodenhuis-Zybert IA, van der Schaar HM, da Silva Voorham JM, van der Ende-Metselaar H, Lei HY, et al. (2010) Immature dengue virus: a veiled pathogen? PLoS Pathog 6: e1000718.
21. Nelson S, Jost CA, Xu Q, Ess J, Martin JE, et al. (2008) Maturation of West Nile virus modulates sensitivity to antibody-mediated neutralization. PLoS Pathog 4: e1000060.
22. Junjhon J, Edwards TJ, Utaipat U, Bowman VD, Holdaway HA, et al. (2010) Influence of pr-M cleavage on the heterogeneity of extracellular dengue virus particles. J Virol 84: 8353-8358.
23. Allison SL, Stiasny K, Stadler K, Mandl CW, Heinz FX, (1999) Mapping of functional elements in the stem-anchor region of tick-borne encephalitis virus envelope protein E. J Virol 73: 5605-5612.
24. Mukhopadhyay S, Kim BS, Chipman PR, Rossmann MG, Kuhn RJ, (2003) Structure of West Nile virus. Science 302: 248.
25. Kuhn RJ, Zhang W, Rossmann MG, Pletnev SV, Corver J, et al. (2002) Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell 108: 717-725.
26. Mukhopadhyay S, Kuhn RJ, Rossmann MG, (2005) A structural perspective of the flavivirus life cycle. Nat Rev Microbiol 3: 13-22.
27. Kaufmann B, Nybakken GE, Chipman PR, Zhang W, Diamond MS, et al. (2006) West Nile virus in complex with the Fab fragment of a neutralizing monoclonal antibody. Proc Natl Acad Sci U S A 103: 12400-12404.
28. Nybakken GE, Oliphant T, Johnson S, Burke S, Diamond MS, et al. (2005) Structural basis of West Nile virus neutralization by a therapeutic antibody. Nature 437: 764-769.
29. Pierson TC, Fremont DH, Kuhn RJ, Diamond MS, (2008) Structural insights into the mechanisms of antibody-mediated neutralization of flavivirus infection: implications for vaccine development. Cell Host Microbe 4: 229-238.
30. Whitehead SS, Blaney JE, Durbin AP, Murphy BR, (2007) Prospects for a dengue virus vaccine. Nat Rev Microbiol 5: 518-528.
31. Roehrig JT, (2003) Antigenic structure of flavivirus proteins. Adv Virus Res 59: 141-175.
32. Colombage G, Hall R, Pavy M, Lobigs M, (1998) DNA-based and alphavirus-vectored immunisation with prM and E proteins elicits long-lived and protective immunity against the flavivirus, Murray Valley encephalitis virus. Virology 250: 151-163.
33. Pincus S, Mason PW, Konishi E, Fonseca BA, Shope RE, et al. (1992) Recombinant vaccinia virus producing the prM and E proteins of yellow fever virus protects mice from lethal yellow fever encephalitis. Virology 187: 290-297.
34. Falconar AK, (1999) Identification of an epitope on the dengue virus membrane (M) protein defined by cross-protective monoclonal antibodies: design of an improved epitope sequence based on common determinants present in both envelope (E and M) proteins. Arch Virol 144: 2313-2330.
35. Vazquez S, Guzman MG, Guillen G, Chinea G, Perez AB, et al. (2002) Immune response to synthetic peptides of dengue prM protein. Vaccine 20: 1823-1830.
36. Dejnirattisai W, Jumnainsong A, Onsirisakul N, Fitton P, Vasanawathana S, et al. (2010) Cross-reacting antibodies enhance dengue virus infection in humans. Science 328: 745-748.
37. Della-Porta AJ, Westaway EG, (1978) A multi-hit model for the neutralization of animal viruses. J Gen Virol 38: 1-19.
38. Pierson TC, Xu Q, Nelson S, Oliphant T, Nybakken GE, et al. (2007) The stoichiometry of antibody-mediated neutralization and enhancement of West Nile virus infection. Cell Host Microbe 1: 135-145.
39. Oliphant T, Nybakken GE, Engle M, Xu Q, Nelson CA, et al. (2006) Antibody recognition and neutralization determinants on domains I and II of West Nile Virus envelope protein. J Virol 80: 12149-12159.
40. Stiasny K, Kiermayr S, Holzmann H, Heinz FX, (2006) Cryptic properties of a cluster of dominant flavivirus cross-reactive antigenic sites. J Virol 80: 9557-9568.
41. Gromowski GD, Barrett ND, Barrett AD, (2008) Characterization of Dengue Complex-specific Neutralizing Epitopes on the Envelope Protein Domain III of Dengue 2 Virus. J Virol 82: 8828-8837.
42. Mehlhop E, Nelson S, Jost CA, Gorlatov S, Johnson S, et al. (2009) Complement protein C1q reduces the stoichiometric threshold for antibody-mediated neutralization of West Nile virus. Cell Host Microbe 6: 381-391.
43. Westaway EG, (1965) The neutralization of arboviruses. II. Neutralization in heterologous virus-serum mixtures with four group B arboviruses. Virology 26: 528-537.
44. Peiris JS, Porterfield JS, (1979) Antibody-mediated enhancement of Flavivirus replication in macrophage-like cell lines. Nature 282: 509-511.
45. Witz J, Brown F, (2001) Structural dynamics, an intrinsic property of viral capsids. Arch Virol 146: 2263-2274.
46. Lok SM, Kostyuchenko V, Nybakken GE, Holdaway HA, Battisti AJ, et al. (2008) Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins. Nat Struct Mol Biol 15: 312-317.
47. Bothner B, Dong XF, Bibbs L, Johnson JE, Siuzdak G, (1998) Evidence of viral capsid dynamics using limited proteolysis and mass spectrometry. J Biol Chem 273: 673-676.
48. Lewis JK, Bothner B, Smith TJ, Siuzdak G, (1998) Antiviral agent blocks breathing of the common cold virus. Proc Natl Acad Sci U S A 95: 6774-6778.
49. Ansarah-Sobrinho C, Nelson S, Jost CA, Whitehead SS, Pierson TC, (2008) Temperature-dependent production of pseudoinfectious dengue reporter virus particles by complementation. Virology 381: 67-74.
50. Halstead SB, (2003) Neutralization and antibody-dependent enhancement of dengue viruses. Adv Virus Res 60: 421-467.
51. Morens DM, Halstead SB, Larsen LK, (1985) Comparison of dengue virus plaque reduction neutralization by macro and "semi-micro' methods in LLC-MK2 cells. Microbiol Immunol 29: 1197-1205.
52. Cherrier MV, Kaufmann B, Nybakken GE, Lok SM, Warren JT, et al. (2009) Structural basis for the preferential recognition of immature flaviviruses by a fusion-loop antibody. EMBO J 28: 3269-3276.
53. Oliphant T, Engle M, Nybakken GE, Doane C, Johnson S, et al. (2005) Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nat Med 11: 522-530.
54. Shrestha B, Brien JD, Sukupolvi-Petty S, Austin SK, Edeling MA, et al. (2010) The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1. PLoS Pathog 6: e1000823.
55. Johnson JE, (2003) Virus particle dynamics. Adv Protein Chem 64: 197-218.
56. Yewdell JW, Taylor A, Yellen A, Caton A, Gerhard W, et al. (1993) Mutations in or near the fusion peptide of the influenza virus hemagglutinin affect an antigenic site in the globular region. J Virol 67: 933-942.
57. Ruprecht CR, Krarup A, Reynell L, Mann AM, Brandenberg OF, et al. (2011) MPER-specific antibodies induce gp120 shedding and irreversibly neutralize HIV-1. J Exp Med 208: 439-454.
58. Finnegan CM, Berg W, Lewis GK, DeVico AL, (2002) Antigenic properties of the human immunodeficiency virus transmembrane glycoprotein during cell-cell fusion. J Virol 76: 12123-12134.
59. Binley JM, Wrin T, Korber B, Zwick MB, Wang M, et al. (2004) Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J Virol 78: 13232-13252.
60. Roehrig JT, Staudinger LA, Hunt AR, Mathews JH, Blair CD, (2001) Antibody prophylaxis and therapy for flavivirus encephalitis infections. Ann N Y Acad Sci 951: 286-297.
61. Mathews JH, Roehrig JT, (1984) Elucidation of the topography and determination of the protective epitopes on the E glycoprotein of Saint Louis encephalitis virus by passive transfer with monoclonal antibodies. J Immunol 132: 1533-1537.
62. Sukupolvi-Petty S, Austin SK, Engle M, Brien JD, Dowd KA, et al. (2010) Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2. J Virol 84: 9227-9239.
63. Mehlhop E, Ansarah-Sobrinho C, Johnson S, Engle M, Fremont DH, et al. (2007) Complement protein C1q inhibits antibody-dependent enhancement of flavivirus infection in an IgG subclass-specific manner. Cell Host Microbe 2: 417-426.
64. Oliphant T, Nybakken GE, Austin SK, Xu Q, Bramson J, et al. (2007) Induction of epitope-specific neutralizing antibodies against West Nile virus. J Virol 81: 11828-11839.
65. Pierson TC, Sanchez MD, Puffer BA, Ahmed AA, Geiss BJ, et al. (2006) A rapid and quantitative assay for measuring antibody-mediated neutralization of West Nile virus infection. Virology 346: 53-65.
66. Davis CW, Mattei LM, Nguyen HY, Ansarah-Sobrinho C, Doms RW, et al. (2006) The location of asparagine-linked glycans on West Nile virions controls their interactions with CD209 (dendritic cell-specific ICAM-3 grabbing nonintegrin). J Biol Chem 281: 37183-37194.
67. Andrewes CH, Elford WJ, (1933) Observations on anti-phage sera. I. he percentage law. Br J Exp Pathol 14: 367-376.
68. Hanna SL, Pierson TC, Sanchez MD, Ahmed AA, Murtadha MM, et al. (2005) N-linked glycosylation of west nile virus envelope proteins influences particle assembly and infectivity. J Virol 79: 13262-13274.
69. Geiss BJ, Pierson TC, Diamond MS, (2005) Actively replicating West Nile virus is resistant to cytoplasmic delivery of siRNA. Virol J 2: 53.